

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

## Assessment of coagulation utilizing thromboelastometry in dogs undergoing orthopedic surgery

**This is a pre print version of the following article:**

*Original Citation:*

*Availability:*

This version is available <http://hdl.handle.net/2318/1524753> since 2024-01-22T09:32:21Z

*Published version:*

DOI:10.1111/vec.12300

*Terms of use:*

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

Assessment of coagulation in dogs undergoing orthopedic surgery utilizing thromboelastometry

### **Abstract**

**Objective** – Evaluation of blood coagulation by means of thromboelastometry in dogs after orthopedic surgery.

**Design** – Longitudinal observational study.

**Setting** – University Veterinary Teaching Hospital.

**Animals** – Thirty-four adult, client-owned dogs.

**Interventions** – Whole blood from each dog was collected by jugular venipuncture (20-gauge needle) using minimum stasis. The blood was then placed into tubes containing 3.8% trisodium citrate (1 part citrate: 9 parts blood) and stored at 37°C.

**Measurements and Main Results** – Dogs undergoing orthopedic surgery were enrolled and whole blood was collected before (T0), at 24 hours (T1) and 1 week (T2) after surgery.

Statistically significant differences ( $p < 0.05$ ) between the values of the thromboelastometry parameters were noted: an increase in maximum clot firmness (MCF) from T0 to T1 in the in-TEM and fib-TEM profiles (both  $p=0.0001$ ), and from T0 to T2 in the in-TEM, ex-TEM, and fib-TEM profiles ( $p=0.012$ ,  $p=0.037$  and  $p=0.0001$ , respectively), and in the  $\alpha$  angle in the in-TEM and ex-TEM profiles ( $p=0.019$  and  $p=0.036$ , respectively), and in the fib-TEM profile from T1 to T2 ( $p=0.039$ ). All parameters were, however, within our institutional reference ranges.

**Conclusions** – This is the first study to assess changes in coagulability by means of thromboelastometry and platelet function analysis in dogs following orthopedic surgery. Our results show that, unlike the increased hypercoagulation observed in human orthopedic patients, a hypercoagulable state did not develop in dogs undergoing orthopedic surgery.

Key words: small animal, hemostasis, surgery, thromboelastometry.

aPTT activated partial thromboplastin time

CFT clot formation time

CT clotting time

MCF maximum clot firmness

PT prothrombin time

TEG thromboelastography

TEM thromboelastometry

THR total hip replacement

## Introduction

Hypercoagulable states are frequent in human patients undergoing surgery. According to a study by McCrath *et al.* (2005), hypercoagulability following non cardiac surgeries develops in 40% of patients.<sup>1</sup> Such conditions, associated with other factors of Virchow's triad (i.e., venous stasis and vessel wall damage), may lead to thrombotic complications, including myocardial infarction, ischemic stroke, deep vein thrombosis and pulmonary embolism.<sup>1</sup>

Numbering among the categories of surgical patients considered at risk for thrombotic complications are those undergoing major orthopedic surgery (new and revision total hip replacement, total knee replacement or fractured neck of femur repair).<sup>2</sup> Studies conducted in human medicine have shown a prothrombotic state in surgical patients; for example, Wilson *et al.* (2001) evaluated hemostasis in 250 patients undergoing surgery for proximal femoral fracture and found hypercoagulability to be correlated with the development of deep venous thrombosis;

Okamura *et al.* (2008) observed hypercoagulability in 30 human patients undergoing total knee, total hip arthroplasty, and other lower extremity orthopedic surgeries.<sup>3,4</sup> The hypothesized causes for the hypercoagulability were surgical trauma with tissue factor expression, systemic inflammation, platelet activation, blood loss, and fluid administration.<sup>1,3</sup> Because of the risk of thrombosis, all human patients receive antithrombotic prophylaxis after orthopedic surgery. Hypercoagulability in dogs after orthopedic surgery has not yet been investigated. In veterinary medicine, a few studies in dogs have described pulmonary embolic complications following cemented total hip replacement (THR).<sup>5,6,7</sup> The pathogenic hypothesis for this event is the elevated femoral intramedullary pressure during stem insertion, ensuing in fat or bone marrow embolization.<sup>8</sup> Pulmonary embolism was not reported in a study on non cemented THR in 11 dogs, where other surgical techniques were applied and pulmonary embolism was diagnosed differently.<sup>9</sup>

Hypercoagulability in postsurgical human patients has been investigated by thromboelastography. Thromboelastography (TEG)/thromboelastometry (TEM) measure the viscoelastic properties of whole blood during the various different phases of clot formation, stabilization and eventual lysis. This complete view of the entire hemostatic process makes the techniques a good instrument to study hypercoagulability. In veterinary medicine, hypercoagulability has been investigated and demonstrated by means of TEG in a variety of disorders, including parvoviral infection, neoplasia, protein-losing enteropathy, hemolytic anemia, disseminated intravascular coagulation and protein-losing nephropathy.<sup>10-15</sup> Recently, Smith *et al.* validated TEM also for the canine species.<sup>16</sup>

Knowing the hemostatic status and its related potential complications is important, especially in intensive care unit patients. In brief, TEM/TEG are new tools for the complete assessment of coagulation.

The aim of this study was the perioperative evaluation of blood coagulation by means of TEM in dogs undergoing orthopedic surgery. Our hypothesis was that in dogs, as in humans, orthopedic surgery may cause hypercoagulability.

## **Materials and methods**

### **Animals**

The study was conducted according to animal welfare considerations and regulations of the Ministry of Health. Dogs undergoing orthopedic surgery between January and September 2009 were enrolled into this prospective clinical study after informed consent was obtained from the owners. The dogs underwent THR, THR revision, double pelvic osteotomy, tibial plateau leveling osteotomy, femoral fracture repair or elbow fracture repair.

The exclusion criteria were: presence of neoplasia, history of a tendency to spontaneous bleeding; positivity to serologic tests for *Leishmania infantum* (titer >1:40; immunofluorescence antibody test), for *Ehrlichia canis*<sup>a</sup>, *Borrelia burgdorferi*<sup>a</sup>, *Anaplasma phagocytophilum*<sup>a</sup> or *Dirofilaria immitis*<sup>a</sup>; administration of corticosteroids in the 4 weeks before surgery.

The patients underwent preoperative evaluation including: physical examination; complete blood count<sup>b</sup>; biochemical profile<sup>c</sup> including albumin, total protein, blood urea nitrogen, creatinine, glucose, alkaline phosphatase, aspartate aminotransferase, alanine aminotransferase,  $\gamma$ -glutamyl transpeptidase, cholesterol, triglyceride and urinalysis (dipstick test<sup>d</sup> and sediment analysis).

Dogs were premedicated with eptadone (0,2 mg/Kg IM) and anesthesia was induced with propofol (2 to 4 mg/Kg IV, to effect). Dogs then were intubated, and anesthesia was maintained by administration of isoflurane in oxygen and air. All dogs were administrated lactated Ringer's solution at a rate of 10 ml/ Kg/h IV. All surgeries were performed by one experienced surgeon (LP) and standardized surgical protocols were used. After the extubation standard postoperative care included the administration of buprenorfine (10 µg/Kg/6-hourly, IV) and carprofen (2 mg/kg/12-hourly, SC or orally with food).

The sample size had been determined using the Kastenbaum, Hoel e Bowman tables for ANOVA;<sup>17</sup> A minimum sample size of 25 animals, repeated for three measurements, was calculated, taking into account: a) a power of the study equal to 80%; b) a significance level of 0.05; c) a standardised range (max-min/sigma) equal to 0.8.

## Hemostasis

Thromboelastometry,<sup>e</sup> PFA-100<sup>f</sup> and platelet count (CBC)<sup>b</sup> were performed at three time points: 1 hour before the surgery (T0), 24 hours after the conclusion of the surgery (T1), and 7 days after surgery (T2).

Blood specimens were collected by jugular venipuncture with a 20 gauge needle by exerting minimal hemostasis on the vessel. Samples obtained with difficulty (e.g. venipuncture requiring numerous attempts, repositions of the needle or interruption in blood flow into the tube) were discarded and the collection was repeated in the contralateral jugular. Samples were stored at 37°C in 3.8% trisodium citrate tubes.<sup>g</sup>

For the thromboelastometry assay, analyses were performed within 30 minutes after blood collection according to the manufacturer's instructions, and the analyses were run for 60

minutes. Three different profiles were tested for each sample: in-TEM, ex-TEM and fib-TEM assays. In the in-TEM assay, the sample is recalcified by the star-TEM<sup>h</sup> reagent and the intrinsic pathway is activated by the in-TEM reagent<sup>i</sup>, whereas in the ex-TEM profile, after recalcification, the extrinsic pathway is triggered by the ex-TEM reagent<sup>l</sup>. In the fib-TEM assay, the extrinsic pathway is activated by tissue factor in the presence of a platelet inhibitor<sup>m</sup> to assess the functional fibrinogen level. The following parameters were assessed for each profile: clotting time ([CT], s); clot formation time ([CFT], s); maximum clot firmness ([MCF]; mm) and  $\alpha$  angle ( $\alpha$ , °).

## Statistical analysis

The data were entered into an *ad hoc* database and analyzed using commercial statistical software<sup>h</sup>. A test for normality based on skewness and on kurtosis was performed to test data distribution. Levene's robust test was used to evaluate the homogeneity of variances. ANOVA was applied to the data to compare the lengths of coagulation time. The Bonferroni's correction was applied. When the data did not fulfill the assumptions of the parametric method, Friedman's two way analysis of variance was performed. The significance level was set at  $p < 0.05$ .

## Results

Of 34 eligible adult dogs candidates for orthopedic surgery, 29 were included at T0 and T1 and 25 at T2 (4 animals were lost to follow-up because the owners did not return for the second visit), and 5 were excluded (1 because of neoplasia, 1 because of filariasis and 3 because of Leishmaniasis). Seven dogs underwent THR, 1 THR revision, 1 double pelvic osteotomy, 16 tibial plateau leveling osteotomy, 3 femoral fracture repair and 1 elbow fracture repair.

Of these 29 dogs, 13 were males and 16 females, aged from 1 to 11 years (age,  $3.64 \pm 2.77$ ). Four dogs were crossbreed, 6 were Labrador Retriever, 2 were Beagle, 1 Cane Corso and 1 German Shepherd; the other breeds included: Boxer, Bull Mastiff, English Bull Dog, Dobermann Pinscher, Dogue de Bordeaux, **Drahthaar (German wire-haired pointer)**, Golden Retriever, Maremma sheepdog, American Pit Bull Terrier, Setter Gordon, and Sharpei. The CBC, biochemical and urinalysis values were all within our institutional reference ranges. The results of the comparisons of the TEM tracings at the three time points (T0 vs T1, T1 vs T2 and T0 vs T2) are listed in Tables 1-3, respectively. Significant differences ( $p < 0.05$ ) were found between T0 and T1, where there was an increase in MCF in the in-TEM and fib-TEM profiles at T1; between T0 and T2, where there was an increase in MCF (in all profiles) and the  $\alpha$  angle (in the in-TEM and ex-TEM profiles) at T2; between T1 and T2, where MCF was increased in the fib-TEM profile at T2. All parameters were within our institutional reference ranges, however (Table 4).<sup>18</sup>

## Discussion

Orthopedic surgery is known to increase the risk for hypercoagulability and thromboembolic complications during the postsurgical period in human patients.<sup>3,4</sup> To the best of the authors' knowledge, coagulation in perioperative dogs has been assessed in a few studies and with different methods. Two studies evaluated the blood coagulation profile after ovariohysterectomy in female dogs: Millis *et al.* (1992) performed standard coagulation profiles (PT, aPTT and fibrinogen), fibrin degradation product, antithrombin III and platelet count; Sobiech *et al.* (2011) carried out standard coagulation profiles, thrombin time, D-dimer and antithrombin activity.<sup>19,20</sup> The first study revealed only a postoperative increase in fibrinogen



level, whereas the second showed a prolonged aPTT, higher fibrinogen and D-dimer concentrations and lower levels of antithrombin activity in the postoperative patient.<sup>19,20</sup> Another study in dogs after gonadectomy evaluated the bleeding tendency in greyhounds according to platelet count, PFA-100, von Willebrand factor, factor VIII, PT, aPTT, fibrinogen, D-dimer, plasminogen, antiplasmin and antithrombin. The results showed a post-operative increase in the fibrinogen level and antiplasmin activity.<sup>21</sup> Altered fibrinolysis was reported by Lanevschi *et al.* (1996) who evaluated plasminogen, tissue plasminogen activator and alpha 2-antiplasmin in dogs after different surgical procedures. Finally, a recent study by Villar *et al.* (2011) showed that aPTT and PT are not predictors of bleeding in greyhounds undergoing gonadectomy, while thromboelastography parameters representing fibrin cross-linking ( $\alpha$  angle) and clot strength (maximum amplitude) were considered predictors of bleeding. Indeed, postsurgical TEG showed a decrease in the  $\alpha$  angle in the bleeder dogs and an increase in the maximum amplitude and  $\alpha$  angle in the non-bleeder dogs.<sup>22</sup>

Thromboelastometry/thromboelastography are useful tools to identify hypo- and hypercoagulable conditions in dogs.<sup>10,11,14,23,24</sup> In the thromboelastometric profiles, CT represents the first phase of fibrin formation, from activation of the test to a clot amplitude of 2 mm; this parameter is mainly affected by the concentration of plasma coagulation factors and coagulation inhibitors (e.g., antithrombin or drugs).<sup>25,26</sup> CFT expresses the velocity of clot formation and is affected predominantly by platelet number and function and by fibrinogen activity. MCF, the maximum firmness reached by the clot, is determined by both platelet number and function and fibrin formation in the presence of factor XIII.<sup>25,26</sup> The  $\alpha$  angle corresponds to the slope of the tangent on the elasticity curve, where a decrease indicates a tendency towards hypocoagulability and an increase a hypercoagulable condition.<sup>25,26</sup>

The TEM profiles in our study showed changes indicating an increase towards a prothrombotic state in dogs undergoing orthopedic surgery; nonetheless, all parameters were within our institutional reference ranges.<sup>18</sup> These changes, as indicated by the increase in MCF and the  $\alpha$  angle, are similar to those Villar *et al.* (2011) reported for the TEG profile after gonadectomy in non-bleeder greyhounds. Also in human studies, TEG showed a greater increase in maximum amplitude (the TEG parameter corresponding to MCF) and  $\alpha$  angle, indicating a condition of hypercoagulability. Wilson *et al.* (2001) identified, in patients following surgery for proximal femoral fracture, a period of hypercoagulability that persisted for 6 weeks, despite the use of antithrombotic prophylaxis. More recently, McCrath *et al.* (2005) reported that the incidence of thrombotic complications in patients undergoing a wide variety of surgical procedures was significantly more frequent, with a maximum amplitude >68 mm.<sup>1,3</sup>

MCF results from the interaction between platelets and fibrinogen activation in the presence of factor XIII, and it does not depend on the presence of procoagulant factors. An increase in this parameter can be due to an increase in fibrinogen concentration, in platelet activity or in the level or activity of factor XIII. Finally, alterations in TEG parameters (prolonged clot formation time and decreased  $\alpha$  angle) following carprofen administration, previously reported by Brainard *et al.*, were not identified in the present study.<sup>27</sup>

This is the first study to assess coagulation status by means of thromboelastometry in dogs following orthopedic surgery. Contrary to what happens in human orthopedic patients, hypercoagulability did not develop in our study population. In human medicine, the mechanisms thought to cause hypercoagulability are surgical trauma with tissue factor expression, systemic inflammation, platelet activation, blood loss and fluid administration.<sup>1,3</sup> Further studies are

needed to explain why a hypercoagulable state does not occur in dogs, despite the presence of at least some of such predisposing factors.

Our results could mean that healthy dogs after orthopedic surgery might be less predisposed than human patients to thrombus formation.<sup>28,29</sup> Venous studies with contrast (e.g., angiography or computed tomography angiography) might be one way to exclude the presence of thromboembolic events, obviating the need antithrombotic prophylaxis in orthopedic postoperative dogs admitted to an intensive care unit.

Finally, further studies are needed to compare the impact of different orthopedic surgeries, the changes in coagulability in a population of older dogs, and the interaction of concomitant pathologies or other predisposing factors (e.g., patients with multiple trauma).

#### ***Footnotes***

<sup>a</sup> Snap 4 DX, IDEXX Laboratories, Westbrook, ME, USA.

<sup>b</sup> ADVIA 120 Hematology, Siemens Healthcare Diagnostics, Tarrytown, NY, USA.

<sup>c</sup> ILAB 300 plus, Clinical Chemistry System, Instrumentation Laboratories, Milan, Italy.

<sup>d</sup> Multistix 10 SG Reagent Strips, Siemens Healthcare Diagnostics, Tarrytown, NY, USA.

<sup>e</sup> ROTEM, TEM innovation GmbH, Munich, Germany.

<sup>f</sup> Venosafe 3.8% buffered sodium citrated, Terumo, Leuven, Belgium.

<sup>g</sup> Stata Statistical Software: Release 11. StataCorp LP, College Station, TX, USA.

<sup>h</sup> Star-TEM 10 (0.2 mol/l CaCl<sub>2</sub> in HEPES buffer pH 7.4 and 0.1% sodium acide in glass vials), TEM innovations GmbH- Munich-Germany.

<sup>i</sup> In-TEM (partial thromboplastin phospholipid made of rabbit brain (chloroform extract), ellagic acid, buffer, preservatives in small glass vials), TEM innovations GmbH- Munich-Germany.

<sup>l</sup> Ex-TEM (recombinant tissue factor and phospholipids, CaCl<sub>2</sub>, preservatives and buffer in small glass vials), TEM innovations Gmbh- Munich-Germany.

<sup>m</sup> Fib-TEM (Cytochalasin D / DMSO solution 0.2 mol/l CaCl<sub>2</sub> in HEPES buffer pH 7.4, preservative in glass vials), TEM innovations Gmbh- Munich-Germany.

## **References**

1. MacCrath DJ, Cerboni E, Frumento RJ et al. Thromboelastography maximum amplitude predicts postoperative thrombotic complications including myocardial infarction. *Anesth Analg* 2005;100(6):1576-1583.
2. Wu O, Clark P, Lowe GDO et al. Thrombophilia and venous thromboembolism after total hip or knee replacement surgery: a systematic review. *J Thromb Haemost* 2004;3(4): 811-813.
3. Wilson D, Cooke EA, McNally MA et al. Changes in coagulability as measured by thromboelastography following surgery for proximal femoral fracture. *Injury* 2001;32(10):765-770.
4. Okamura K, Nakagawa I, Hidaka S et al. Perioperative changes of blood coagulability evaluated by thromboelastography (TEG) in patients undergoing total knee and total hip arthroplasty. *Masui* 2008;57(10):1207-1212.
5. Otto K, Matis U. Changes in cardiopulmonary variables and platelet count during anesthesia for total hip replacement in dogs. *Vet Surg* 1994;23(4):266-273.
6. Liska WD, Poteet BA. Pulmonary embolism associated with canine total hip replacement. *Vet Surg* 2003; 32(2):178-186.
7. Reindl S, Matis U. Detection of embolic events by capnography and trans-oesophageal echocardiography during total hip replacement. *Vet Comp Orthop Traumatol* 1998;11(2):68-75.

- 251 8. Kim Y-H, Oh SW, Kim JS. Prevalence of fat embolism following bilateral simultaneous and  
252 unilateral total hip arthroplasty performed with or without cement. *J Bone Joint Surg Am*  
253 2002;84(8):1372-1379.
- 254 9. Tidwell SA, Graham JP, Peck JN, Berry CR. Incidence of pulmonary embolism after non-  
255 cemented total hip arthroplasty in eleven dogs: computed tomographic pulmonary angiography  
256 and pulmonary perfusion scintigraphy. *Vet Surg* 2007;36(1):37-42.
- 257 10. Otto CM, Rieser TM, Brook MB. Evidence of hypercoagulability in dogs with parvoviral  
258 enteritis. *J Am Vet Med Assoc* 2000;217(10):1500-1504.
- 259 11. Kristensen AT, Wiinberg B, Jessen LR et al. Evaluation of human recombinant tissue  
260 factor-activated thromboelastography in 49 dogs with neoplasia. *J Vet Intern Med*  
261 2008;22(1):140-147.
- 262 12. Goodwin LV, Goggs R, Chan DL, Allenspach K. Hypercoagulability in dogs with protein-  
263 losing enteropathy. *J Vet Intern Med* 2011; 25(2):273-277.
- 264 13. Fenty RK, DeLaforcade AM, Shaw SP, O'Toole TE. Identification of hypercoagulability in  
265 dogs with primary immune-mediated hemolytic anemia by means of thromboelastography. *J Am*  
266 *Vet Med Assoc* 2011;238(4):463-467.
- 267 14, Wiinberg B, Jensen AL, Johansson PI et al. Thromboelastography evaluation of hemostatic  
268 function in dogs with disseminated intravascular coagulation. *J Vet Intern Med* 2008;22(2):357-  
269 365.
- 270 15. Donahue SM, Brooks M, Otto CM. Examination of hemostatic parameters to detect  
271 hypercoagulability in dogs with severe protein-losing nephropathy. *J Vet Emerg Crit Care*  
272 2011;21(4):346-355.

- 273 16. Smith SA, McMichael M, Galligan A et al. Clot formation in canine whole blood as  
274 measured by rotational thromboelastometry is influenced by sample handling and coagulation  
275 activator. *Blood Coagul Fibrinolysis* 2010;21(7):692-702.
- 276 17. Woolson RF and Clarke WR. Comparing More Than Two Groups of Observations: Analysis  
277 of Variance for Comparing Groups. In John Wiley & Sons (ed.), *Statistical Methods for the*  
278 *Analysis of Biomedical Data* 2002, second ed. , Inc. Publications.
- 279 18. Falco S, Bruno B, Maurella C et al. Hypocoagulation in dogs secondary to hydroxyethyl  
280 starch (130/0.4) dilution: in vitro study by means of thromboelastometry. Accepted for  
281 publication by J Vet Emerg Crit Care (JVECC-11-09-0004.R3).
- 282 19. Millis DL, Hauptman JG, Richter M. Preoperative and postoperative hemostatic profiles of  
283 dogs undergoing ovariohysterectomy. *Cornell Vet.* 1992;82(4):465-70.
- 284 20. Sobiech P, Targoński R, Stopyra A, Zarczyńska K. Changes in the blood coagulation profile  
285 after ovariohysterectomy in female dogs. *Pol J Vet Sci* 2011;14(2):289-90.
- 286 21. Lara-García A, Couto CG, Iazbik MC, Brooks MB. Postoperative bleeding in retired racing  
287 greyhounds. *J Vet Intern Med* 2008;22(3):525-33.
- 288 22. Vilar Saavedra P, Stingle N, Iazbik C, Marín L, McLoughlin MA, Xie Y, Couto G.  
289 Thromboelastographic changes after gonadectomy in retired racing greyhounds. *Vet Rec*  
290 2011;169(4):99.
- 291 23. Wiinberg B, Jensen AL, Rozanski E et al. Tissue factor activated thromboelastography  
292 correlates to clinical signs of bleeding in dogs. *Vet J* 2009;179(1):121-129.
- 293 24. Wagg CR, Boysen SR, Bédard C. Thromboelastography in dogs admitted to an intensive care  
294 unit. *Vet Clin Pathol* 2009;38(4):453-461.

25. Kol A, Borjesson DL. Application of thromboelastography/thromboelastometry to veterinary medicine. *Vet Clin Pathol* 2010;39(4):405-416.
26. McMichael MA, Smith SA. Viscoelastic coagulation testing: technology, applications and limitations. *Vet Clin Pathol* 2011;40(2):140-153.
27. Brainard BM, Meredith CP, Callan MB et al. Changes in platelet function, hemostasis, and prostaglandin expression after treatment with nonsteroidal anti-inflammatory drugs with various cyclooxygenase selectivities in dogs. *Am J Vet Res* 2007;68(3):251-257.
28. Thromboembolic Risk Factors (THRIFT) Consensus Group. Risk of and prophylaxis for venous thromboembolism in hospital patients. *BMJ* 1992;305(6853):567-74.
29. Heit J. Epidemiology of venous thromboembolism. In: Colman RW, Marder VJ, Clowes AW et al., editors. *Hemostasis and Thrombosis*. 5th ed. Philadelphia: Lippincott W. & W.; 2006, 1227-1233.

**Table 1:** Comparison between thromboelastometry values obtained at T0 (n=29) and T1 (n=29).

	<b>CT<sup>§</sup> s</b>		<b>CFT<sup>  </sup> s</b>		<b>MCF<sup>¶</sup> mm</b>		<b><math>\alpha^{**}</math> degree</b>	
	<b>T0</b>	<b>T1</b>	<b>T0</b>	<b>T1</b>	<b>T0</b>	<b>T1</b>	<b>T0</b>	<b>T1</b>
<b>in-TEM</b>	178.8 (118-390)	176.03 (134-263)	96.83 (52-202)	78.67 (47-145)	63.23 (53-74)	68.8* (59-86) p=0.0001	72.27 (55-80)	75.5 (62-81)
<b>ex-TEM</b>	49.59 (31-81)	48.59 (32-66)	111.34 (60-215)	95.59 (53-223)	61.48 (48-75)	67.86 (49-78)	69.03 (55-79)	71.48 (51-80)
<b>fib-TEM</b>	48.7 (25-77)	48.26 (26-84)	na	na	15.76 (5-36)	18.4* (6-35) p=0.0001	68.29 (50-82)	73.85 (63-81)



Values are expressed as median (minimum-maximum); na, not applicable.

\* statistically significant differences between the control and the postsurgical group ( $p < 0.05$ );

§ clotting time; || clot formation time; ¶ maximum clot firmness; \*\*  $\alpha$  angle.

**Table 2:** Comparison between thromboelastometry values obtained at T1 (n=29) and T2 (n=25).

	CT <sup>§</sup> s		CFT <sup>  </sup> s		MCF <sup>¶</sup> mm		$\alpha$ <sup>**</sup> degree	
	T1	T2	T1	T2	T1	T2	T1	T2
<b>in-TEM</b>	176.03 (134-263)	160.54 (118-224)	78.67 (47-145)	62.38 (37-92)	68.8 (59-86)	69.07 (56-79)	75.5 (62-81)	78.38 (73-82)
<b>ex-TEM</b>	48.59 (32-66)	43.84 (33-55)	95.59 (53-223)	70.56 (41-129)	67.86 (49-78)	69.6 (55-78)	71.48 (51-80)	76.04 (65-82)
<b>fib-TEM</b>	48.26 (26-84)	41.57 (33-55)	na	na	18.4 (6-35)	25.96* (13-36) p=0.039	73.85 (63-81)	75.34 (61-83)

Values are expressed as median (minimum-maximum); na, not applicable.

\* statistically significant differences between the postsurgical groups ( $p < 0.05$ );

§ clotting time; || clot formation time; ¶ maximum clot firmness; \*\*  $\alpha$  angle.

**Table 3:** Comparison between thromboelastometry values obtained at T0 (n=29) and T2 (n=25).

	CT <sup>§</sup> s		CFT <sup>  </sup> s		MCF <sup>¶</sup> mm		$\alpha$ <sup>**</sup> degree	
	T0	T2	T0	T2	T0	T2	T0	T2
<b>in-TEM</b>	178.83 (118-390)	160.54 (118-224)	96.83 (52-202)	62.38 (37-92)	63.23 (53-74)	69.08* (56-79) p=0.012	72.26 (55-80)	78.38* (73-82) p=0.019
<b>ex-TEM</b>	49.59 (31-81)	43.84 (33-55)	111.34 (60-215)	70.56 (41-129)	61.48 (48-75)	69.6* (55-78) p=0.037	69.03 (55-79)	76.04* (65-82) p=0.036
<b>fib-TEM</b>	48.7 (25-77)	41.58 (33-55)	na	na	15.76 (5-36)	25.96* (13-36) p=0.0001	68.29 (50-82)	75.34 (61-83)

Values are expressed as median (minimum-maximum); na, not applicable.

\* statistically significant differences between the control and the postsurgical group ( $p < 0.05$ );

§ clotting time; || clot formation time; ¶ maximum clot firmness; \*\* $\alpha$  angle.

**Table 4:** Comparison of our institutional reference ranges for ROTEM tests (n=45) and values measured at T0, T1 and T2.

Test	in-TEM				ex-TEM	
	T0	T1	T2	Range	T0	T1
CT <sub>s</sub> §	178.83	176.03	160.54	126-363	49.59	48.59
CFT <sub>s</sub>	96.83	78.67	62.38	47-224	111.34	95.59
MC <sub>F</sub> ¶	63.23	68.8	69.08	50-75	61.48	67.86
$\alpha$ ° **	72.26	75.5	78.38	55-81	15.76	71.48

		fib-TEM				
T2	Range	T0	T1	T2	Range	
43.84	29-92	48.7	48.26	41.58	14-102	
70.56	54-275	na*	na*	na*	na*	
69.6	36-73	15.76	18.4	25.96	6-26	
76.04	47-79	68.29	73.85	75.34	48-78	

T0, T1 and T2 values are expressed as median; Range values are expressed as 5<sup>th</sup>-95<sup>th</sup> percentile (95% confidence intervals); \* not applicable;

§ clotting time; || clot formation time; ¶ maximum clot firmness; \*\*  $\alpha$  angle.

372

373

374

375

376

377

378

379